Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452162 · ClinicalTrials.gov registry record · NA
Physiologic MR Imaging of Salivary Gland Tumors
A NA study of Salivary Gland Tumor, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04452162: Recruiting NA study of Salivary Gland Tumor, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04452162 is a NA study of Salivary Gland Tumor that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452162, a NA study of Salivary Gland Tumor, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Primary Outcome
Differentiation of malignant from benign neoplasms and progression free survival at 6 month starting from end of chemo-radiation treatment
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT04452162 shows while recruiting
NCT04452162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Salivary Gland Tumor appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT04452162 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04452162 about?
NCT04452162 is a clinical study titled "Physiologic MR Imaging of Salivary Gland Tumors". The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
What is the current status of trial NCT04452162?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-08-25. Estimated completion is 2026-06.
What conditions does trial NCT04452162 study?
This clinical trial studies the following conditions: Salivary Gland Tumor.
What interventions are being tested in trial NCT04452162?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04452162?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452162 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04452162's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI